Evidence map›Paper›PMID 40821486›Full record

ArticleProceedings (Baylor University. Medical Center)2025

Insulin resistance, metabolic dysfunction-associated steatotic liver disease, and advanced liver fibrosis in lean US adults: a population-based study.

Basile Njei, Manasik Abdu, Yazan A Al-Ajlouni, Mouhand F Mohamed, Yangyang Deng, Eri G Osta, Ulrick Sidney Kanmounye, Silvia Vilarinho, Jonathan Dranoff, Joseph K Lim and 2 more

Abstract read
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Basile NjeiSection of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-0714-4368
Manasik AbduUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.
Yazan A Al-AjlouniDepartment of Medicine, Staten Island University Hospital, Staten Island, New York, USA.ORCID https://orcid.org/0000-0002-1718-4964
Mouhand F MohamedBrown University, Providence, Rhode Island, USA.
Yangyang DengJohns Hopkins University, Baltimore, Maryland, USA.
Eri G OstaThe University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Ulrick Sidney KanmounyeHarvard Medical School, Boston, Massachusetts, USA.
Silvia VilarinhoSection of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Jonathan DranoffSection of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Joseph K LimSection of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
MdSection of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Justin Basile Echouffo TcheuguiJohns Hopkins University, Baltimore, Maryland, USA.

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
NIDDK NIH HHS P30 DK034989
6 · The paper itself

Abstract

Background: While insulin resistance (IR) and metabolic dysfunction-associated steatotic liver disease (MASLD) are well established in obese individuals, their connection in lean populations remains underexplored. Methods: This cross-sectional study investigated the relations of IR with MASLD and advanced liver fibrosis based on data from the 2017-2020 US National Health and Nutrition Examination Surveys. The subjects were lean adults (non-Asian body mass index [BMI] < 25 kg/m Results: Among 860 lean adults (median age 53 years; 48% female; 38% White; mean BMI 22.5 kg/m Conclusion: MASLD and advanced liver fibrosis in lean individuals are linked to IR, independently of excess adiposity. Assessing IR could aid in identifying lean individuals at high risk of MASLD and liver fibrosis, regardless of diabetes status.

Indexed as

Advanced liver fibrosisinsulin resistancemetabolic dysfunctionsteatotic liver disease

Identifiers

PMID40821486
PMCPMC12351751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.